Kabelline
Kabelline is marketed as a Korean fat-reduction solution containing deoxycholic acid. Public product pages identify an 8 mL × 5-vial presentation, but the reviewed material does not provide a reliable quantitative formulation, a regulator-hosted label, or a complete map of developer, manufacturer, authorization-holder, and distributor roles.
Quick reference
Section titled “Quick reference”| Field | Kabelline |
|---|---|
| Declared principal ingredient | Deoxycholic acid |
| Presentation | 8 mL × 5 vials |
| Quantitative concentration | Not established from the reviewed official or regulatory material |
| Product category | Marketed as an injectable fat-reducing serum or fat-dissolving solution; legal classification requires local verification |
| United States status | Not FDA approved as a fat-dissolving injection |
| Company context | Listed and sold by JDBIO; exact brand-owner and manufacturing roles are not established by that listing alone |
| Main evidence boundary | A named ingredient does not make Kabelline equivalent to Kybella or transfer Kybella’s approval and evidence |
JDBIO’s current product page supplies the ingredient-level declaration and package size (JDBIO Kabelline 🔗). The page is a commercial listing, not a regulator-hosted label or independent compositional analysis.
Declared formulation
Section titled “Declared formulation”JDBIO identifies Kabelline simply as Deoxycholic Acid and describes it as an injectable fat-reducing serum. It lists five 8 mL vials per box. This supports a material-family and presentation statement, but not a complete finished-product specification.
The reviewed public material does not reliably establish:
- deoxycholic-acid concentration or total amount per vial
- salt form and pH
- complete excipient list
- sterility and endotoxin specifications
- route and intended-use language from a current regulator-hosted label
- whether the displayed product is identical across every export market
Some distributor pages publish numerical ingredient values, but ambiguous units and the absence of a primary specification make them unsuitable for a clinical reference. The concentration should remain not verified until a current label, IFU, registration record, or validated manufacturer specification is available.
Product identity is not ingredient equivalence
Section titled “Product identity is not ingredient equivalence”Deoxycholic acid can disrupt cell membranes, but that ingredient-level mechanism does not establish equivalence among finished products. Kabelline should be distinguished from Kybella by at least:
- concentration and delivered amount
- excipients, pH, and presentation
- manufacturing and quality records
- approved indication and anatomy
- dosing framework
- clinical evidence and pharmacovigilance
The phrase FDA-approved deoxycholic acid, sometimes used in sales copy, is misleading when applied to Kabelline. FDA approval attaches to a defined finished drug, applicant, formulation, label, and indication—not to every marketed product that names the same molecule.
Company-role uncertainty
Section titled “Company-role uncertainty”JDBIO includes Kabelline in its fat-dissolver catalogue and sells the product through its website. That supports a current seller or commercial-channel relationship. The listing does not, by itself, prove that JDBIO developed the formula, physically manufactured it, owns the brand in every market, or holds a national drug authorization.
Use the narrowest relationship supported by the exact package and local record. If another exporter or distributor appears on a listing, do not promote that company to manufacturer without corroborating documentation.
United States status
Section titled “United States status”The FDA specifically names Kabelline among fat-dissolving injections marketed and sold online that are not FDA approved. It reports serious adverse reactions after unapproved fat-dissolving injections as a category and warns consumers not to purchase such products online for self-injection (FDA safety communication 🔗).
The FDA statement establishes US status. It does not determine Kabelline’s status in every other jurisdiction. For any non-US market, a current national authorization or registration record should be checked directly.
Evidence and safety boundary
Section titled “Evidence and safety boundary”No product-specific efficacy or comparative claim should be derived from Kabelline’s use of deoxycholic acid alone. Likewise, the adverse events described by FDA for the wider unapproved-injection category are not Kabelline-specific incidence data.
Commercial sources may provide injection maps, dose volumes, needle depths, or treatment intervals. Those are not reproduced here because the reviewed sources did not establish a current authorized label or transferable protocol. The lack of a verified label also limits confident interpretation of contraindications, storage, use window, and adverse-event management.
Practitioner interpretation
Section titled “Practitioner interpretation”Before recording Kabelline as a clinical product, verify the exact outer box and vial, ingredient statement, lot and expiry, supplier, storage history, legal manufacturer, and local authorization status. Deoxycholic acid on a product page is a starting identity claim, not a substitute for that documentation.
Nearby reference pages
Section titled “Nearby reference pages”- Fat-Reduction Injectables maps formulation and regional authorization as separate dimensions.
- Aqualyx illustrates a different deoxycholate-derived system and a current cosmetic-labeling issue.
- Lipo Lab covers a multi-variant family associated with PPC/deoxycholate declarations.